Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Receptagen Ltd. -- Ignore unavailable to you. Want to Upgrade?

To: Paul Thomas who wrote (87)	5/1/1998 5:26:00 PM
From: Wizzer	Respond to of 203

I am not a holder of this stock, but have a friend who owns shares. I certainly hope everything works out and this is just a minor "bump". I think it is.

To: Paul Thomas who wrote (87)	5/2/1998 7:14:00 PM
From: Wizzer	Read Replies (1) \| Respond to of 203

ARTICLE ON RCG: Saturday, May 2, 1998 Trading in Receptagen held as CEO meets TSE officials By DREW HASSELBACK Vancouver Bureau The Financial Post The Toronto Stock Exchange has suspended trading in struggling Receptagen Ltd. of Edmonds, Wash. Ralph Shay, the exchange's vice-president of company listings and regulation, said Friday the suspension was because the company had failed to meet a minimum net capital requirement of $1 million and equity value of $10 million. Receptagen now has one year to meet the TSE's requirements. If it fails to do so, it will be delisted. President and chief executive Warren Wheeler was not available for comment Friday. Callers to the firm's head office were told he was in Toronto to discuss the suspension with TSE officials. The pharmaceutical firm has two subsidiaries developing drugs to treat cancer, stroke and AIDS. In March, the company announced it was calling off a $30-million merger with Scitech Genetics Ltd. of Singapore. Receptagen then said it was "very, very actively" pursuing an alternative financial agreement with a third party. Before the suspension Thursday, Receptagen shares (rcg/tse) last traded at 3.5«. Their 52-week range is 8« to 20«.